The anticonvulsant properties of VPA (valproic acid), a branched short-chain fatty acid, were serendipitously discovered in 1963. Since then, therapeutic roles of VPA have increased to include bipolar disorder and migraine prophylaxis, and have more recently been proposed in cancer, Alzheimer's disease and HIV treatment. These numerous therapeutic roles elevate VPA to near 'panacea' level. Surprisingly, the mechanisms of action of VPA in the treatment of many of these disorders remain unclear, although it has been shown to alter a wide variety of signalling pathways and a small number of direct targets. To analyse the mechanism of action of VPA, a number of studies have defined the structural characteristics of VPA-related compounds giving rise to distinct therapeutic and cellular effects, including adverse effects such as teratogenicity and hepatotoxicity. These studies raise the possibility of identifying target-specific novel compounds, providing better therapeutic action or reduced side effects. This short review will describe potential therapeutic pathways targeted by VPA, and highlight studies showing structural constraints necessary for these effects.
Introduction
Understanding epilepsy and developing novel compounds for seizure control has been greatly facilitated by the availability of experimental models to reproduce seizures in the laboratory. One of these models, seizures induced by PTZ (pentylenetetrazol), was used in 1963 by Meunier et al. [1] , who accidentally identified VPA (valproic acid) as a potential epilepsy treatment. Since then, VPA has developed into one of the most frequently used anti-epileptic drugs worldwide, and in addition is now being used for the treatment of many other conditions, including BD (bipolar disorder) [2] and migraine [3] (Figure 1 ). It has also been proposed in cancer [4] , AD (Alzheimer's disease) [5] and latent HIV treatment [6] , in addition to having a variety of side effects, including hepatotoxicity and teratogenicity. Many of these effects of VPA are indirect and/or occur via an unknown mechanism [7] .
In the present review, we discuss potential therapeutic mechanisms of VPA and highlight what is known concerning VPA congener specificity in the treatment of epilepsy and BD, the effect of teratogenicity (giving rise to potential roles in cancer and HIV treatment) and other medical effects.
Epilepsy
The ability to recreate seizures in living animals, or in neuronal slice models for epilepsy, has allowed VPA congeners with similar or increased therapeutic efficacy to be identified. Although this approach has not identified the therapeutic mechanism of the drug so far, it has helped in the development of new treatments.
Structure-function studies of VPA congeners were originally initiated since it was thought that metabolites of VPA were responsible for its anticonvulsant activity. In these experiments, a wide variety of VPA-related compounds have shown increased potency (Figure 2 ), initially with structures of the same approximate size of VPA (six to eight carbon atoms) [8] and subsequently with longer carbon chains showing greater anticonvulsant activity than VPA [9] . The position of branching in these molecules has a strong effect on activity [10] , and additional methyl branching at the α-position (the carbon adjacent to the carboxy group; Figure 2 ) considerably enhances potency [11] . Changing the carboxy headgroup to amide [11, 12] , HA (hydroxamic acid) [13] or urea [14] causes increased activity compared to the corresponding acid. Amides with an unsubstituted β-position (where the second carbon from the carboxy group is in the form 'CH 2 '; Figure 2 ) metabolize to their corresponding acids, but non-metabolizing compounds such as PID (propylisopropyl acetamide) and VCD (valnoctamide) are more active [15] . Double bonds confer higher chemical reactivity in some cases, which is associated with higher anticonvulsant potency [16] . Cyclic congeners with an α-position branch point [11, 17] , e.g. TMC (tetramethylcyclopropane) amide [18, 19] and urea [20] derivatives, are stable and effective anticonvulsants. Fluorination of VPA-HA [21] and TMC compounds [22] in the α-position (as seen with branching) markedly increases the anticonvulsant activity, with some compounds being up to 120 times more potent than VPA itself. It is important to note that many of these studies measure both VPA congener efficacy in blocking seizures and other characteristics such as half life and blood-brain barrier permeability, which may affect drug action [23] ; for example, amide derivatives reach higher brain concentrations than corresponding acids [24] .
Although the breadth of compounds blocking seizures in animal models has not defined a core structure for VPA-like compounds required for this effect, a correlation has been shown between the anticonvulsant effect and partition coefficients of VPA-related compounds [17] . This suggests that more lipophilic compounds are more likely to be better in seizure control. QSAR (quantitative structure-activity relationship) analysis of a number of VPA analogues and metabolites reinforced the importance of lipophilicity, in addition to finding higher activity for α-substituted compounds ( Figure 2 ) [25] .
To better understand the action of VPA and related compounds in seizure control, considerable research has examined the two main molecular targets of VPA linked to epilepsy, GABA (γ -aminobutyric acid) breakdown and ion channel inhibition (Figure 1 ).
GABA levels
VPA has been reported to elevate the levels of the inhibitory neurotransmitter GABA by direct inhibition of GABA transaminase [26] and succinic semialdehyde dehydrogenase [27] , which are enzymes responsible for GABA breakdown.
Early studies showed that GABA levels are elevated by VPA and some, but not all, potent anticonvulsant analogues [9, 23] . In these studies, branched analogues increased GABA levels, whereas unbranched compounds had no effect [10] , and α-fluorinated VPA also led to increased GABA levels compared with VPA [28] , findings consistent with the structural constraints observed for seizure prevention. However, in a recent study, VPA, VPD (valpromide, the amide derivative of VPA) and VCD (Figure 2 ), all compounds used in clinical epilepsy treatment, did not elevate extracellular hippocampal GABA [29] .
Ion channels
A number of studies identified an inhibitory effect of VPA on a variety of ion channel activities [30, 31] , including the indirect inhibition of sub-threshold slow sodium currents and membrane-depolarizing rectification [30] , and calcium currents [31] . The role of ion channels in neuronal excitability has been clearly demonstrated, and a large number of papers have reported that VPA blocks neuronal excitability, and particularly high-frequency action potential firing [32] . However, many of these studies use high VPA concentrations and it is unclear whether this effect is directly on ion channels or through indirect means, and only one VPA congener has been shown to directly bind to sodium channels [33] . The pathogenesis of migraine has also been proposed to involve a hyperexcitable state due to cortical spreading depression, and VPA normalizes neuronal firing and increases the threshold for neuronal discharge [34] , an effect that may occur through ion channel inhibition as shown for other joint epilepsy/migraine treatments.
Bipolar disorder
VPA is commonly used in BD prophylaxis, and, as with epilepsy treatment, the mechanism of action of VPA remains unclear ( Figure 1 ). To further BD research and to test new therapeutic compounds, a number of laboratory-based animal model systems have been developed [35] . Although the functionality of these models is still to be validated, the ultimate demonstration for new drug efficacy is clearly clinical trials. A limited number of VPA-related compounds ( Figure 2 ) have been used in BD clinical trials, based on efficacy in seizure control or in animal models for BD, or due to common effects on known molecular targets. VPD has been shown to be effective in acute psychotic states, leading to a reduction of agitation and reduced hospitalization [36] . VCD, after being investigated for use in epilepsy, was used in a Phase II clinical trial in 2008 [37] . VGD (N-valproylglycinamide), a glycine derivative of VPA, has been shown to attenuate amphetamine-induced increases in rearing in a hyperactivity rat model of mania and it has subsequently been successfully used in Phase II clinical trials and is currently being licensed for development as a BD drug [38] . PID is also currently in development as an anticonvulsant and BD drug [39] . An alternative approach employed in BD research is to use current BD treatments of distinct structure such as lithium, VPA and carbamazepine to identify and characterize BD drug targeted signalling pathways (Figure 1 ). This approach then eliminates the need for artificial models recreating the disorder. These studies have led to four proposed therapeutically relevant signalling pathways, although few studies have identified VPA-specific congeners for each effect.
Inositol and phospholipid signalling
In 1989, the depletion of cellular inositol by the reduction of inositol recycling was proposed as a mechanism of action of lithium in BD [40] , and, since then, lithium, VPA and carbamazepine have all been shown to reduce InsP 3 levels in several model systems [41] [42] [43] [44] . Owing to difficulties in measuring InsP 3 , researchers have developed a test whereby BD treatments cause an inositol-depletion-dependent increase in the growth cone size of primary neurons [42, 43] . These experiments do not comprehensively define structural characteristics causing inositol depletion; however, they do show that these active structures are unrelated to those causing teratogenicity, and that some carboxylic acids show high activity in both inositol depletion and seizure control.
Structural constraints for inositol depletion in neurons suggest that a carboxy headgroup is necessary, with increasing potency by branching at the β-position, with, for example, DIA (di-isopropyl acetic acid) PIA (propylisopropyl acetic acid) VCA (valnoctic acid) (Figure 2 ) [43] . Changing the carboxy acid group to amide or hydroxamide groups generally strongly reduces activity, with the exception of cyclopropyl analogues that must be modified at the carboxy group [e.g. MTMCD (N-methyl-2,2,3,3-tetramethylcyclopropanecarboxamide) ] to show activity [43] . Furthermore, the effect of unsaturated VPA analogues is stereoselective, with S enantiomers being more powerful, and, unlike for teratogenicity, a hydrogen at the β-position is not required to cause inositol depletion [42] .
The inositol-depletion effect of VPA is likely to be caused through an unknown mechanism to reduce MIP (myoinositol 1-phosphate) synthase activity [44, 45] , thus reducing de novo inositol biosynthesis. This causes a follow-on reduction in InsP 3 and phosphatidylinositol phosphate production (including PtdInsP, PtdInsP 2 and PtdInsP 3 ) [46] . The few structures that have been shown to inhibit MIP synthase directly, VPA and two amide derivatives, VCD and VGD, have all been tested clinically for BD treatment [44] ; however, these amide derivatives are not active in the inositol-depletion growth cone assays [43] . Interestingly, the non-competitive mode of MIP synthase inhibition of VCA is changed to competitive by amidation to VCD in these direct assays [44] .
GSK3 (glycogen synthase kinase 3)
Many studies on the cellular targets of BD drugs focus on the lithium-sensitive enzyme GSK3β, a protein involved in cellcycle progression, neuronal structure and cell survival. This enzyme has been suggested as a BD drug target since GSK3β-knockout or inhibitor-treated mice show reduced depressionand manic-like behaviour [47] . Inhibition of GSK3β by VPA has been proposed to act through both direct and indirect mechanisms [48] , although this effect is disputable [49] . VPA congener studies on this effect either show no direct inhibitory effect of any compound tested [42] or a strong direct effects of discrete structures, with no correlation between inhibition potency and anticonvulsant efficacy [50] .
MAPK (mitogen-activated protein kinase) and neuroprotection
Activation of the MAPK pathway is caused by VPA and other BD drugs [51] [52] [53] . This effect of VPA may provide a therapeutic role, since BD is associated with a loss of brain volume in discrete regions [54] and MAPK activation gives rise to a neuroprotective effect. Although the mechanism of this activation remains unclear, one study suggests that VPA may cause this effect through attenuation of the PKA (protein kinase A) pathway in the simple biomedical model Dictyostelium [51] , and we have shown that this effect is shared by 2M2P (2-methyl-2-pentenoic acid) (Figure 2f ). It is currently unclear whether this effect is related to improved spatial learning and memory following treatment with 2-pentyl-4-pentynoic acid (Figure 2h ), an effect showing enantiomeric specificity [55, 56] , or is due to altered cAMP signalling [57] .
VPA reduces PLA 2 -catalysed arachidonic acid release [58] , and other BD treatments down-regulate PLA 2 transcription, making this pathway a potential target in BD treatments [58, 59] . PLA 2 may also function in seizure progression, since PLA 2 -catalysed overproduction of arachidonic acid has been shown in the brain following seizures, resulting in overactivated neurotransmission. The mechanism of VPA-catalysed PLA 2 inhibition remains unclear, although we have shown VPA congener-specificity of this inhibition in Dictyostelium (N. Pawolleck and R.S.B. Williams, unpublished work).
Teratogenicity, cancer and latent HIV treatment
The discovery of a direct inhibitory effect of VPA on HDACs (histone deacetylases) [61] provided a breakthrough in our understanding of one of the major side effects, teratogenicity, as well as explaining the potential basis for VPA treatment of cancer and latent HIV (Figure 1) .
Structural definitions of teratogenicity have advanced rapidly, owing to the availability of whole animal models for this effect. Teratogenicity has been proposed to require branching at the α-position ( Figure 2 ) and a side chain longer than a methyl group [62, 63] . Increasing the length of the side chain increases the teratogenic potential [64] . Substitution of the α-position hydrogen abolishes teratogenicity. Unsaturated bonds also influence activity, where, for example, introduction of a ω−2 double bond (on the second carbon from the end distal to the carboxylic acid) in related compounds abolishes teratogenicity, whereas a ω−4 double bond has no effect [65] . Additional branching of the side chain reduces teratogenic effects without altering the anticonvulsant profile [66] . Teratogenicity is a stereoselective effect [67] with S enantiomers proving much more active than their corresponding R enantiomer. Teratogenic effects have also been observed in patient studies, whereby VPA treatment during pregnancy is associated with an increased risk of neural tube defects such as spina bifida aperta and other malformations [65] . Thus the identification of novel VPA-related compounds lacking these teratogenic effects may provide valuable new treatments. For example, TMC-related compounds [18] , fluorinated VPA and HA derivatives [21] are significantly less teratogenic than VPA, but all show high seizure control activity (Figure 2) .
The molecular basis for VPA teratogenicity is likely to be through a direct inhibition of HDACs, since VPA inhibits class I and II HDAC enzymes directly [6] . Inhibition of HDAC activity gives rise to hyperacetylation of gene promoters, and altered expression of approx. 2% of the genome [68] . Inhibition of HDACs has been associated with tumour cell toxicity [69] and was shown to be linked to teratogenicity for carboxylic acids [70] . Potential teratogenic effects of amides or hydroxamides may occur through metabolic conversion into corresponding acids [71] . This inhibitory effect may also give rise to the anti-proliferative and prodifferentiative mechanisms of VPA and its derivatives. Cellbased assays for these mechanisms, used to predict teratogenicity of new compounds [72, 73] , can be used in the analysis of VPA's anticancer function [74] . The carboxy headgroup is required for anti-proliferative and pro-differentiative effects, the α-carbon must contain a hydrogen atom and two alkyl groups, with one alkyl group being saturated, and effects are enhanced by triple bonds [67] , structural constraints consistent with an action through HDAC inhibition.
HDAC inhibitory action makes VPA a potential treatment for latent HIV. Eradication of HIV-1 is prevented by persistent infection in resting CD4
+ T-cells. HDAC-1 is responsible for maintaining latency of integrated HIV. It has been shown that VPA can induce HIV expression from resting CD4
+ T-cells without increasing susceptibility to de novo HIV infection. In a proof of concept study, viral load significantly declined after combination treatment with VPA and highly active antiretroviral therapy [6] . It is plausible that HIV infection could be cured by treatment with VPA or more potent analogues in combination with more effective antiretroviral drugs.
Other mechanisms associated with the teratogenic effects of VPA include reducing folate metabolism and activating PPARδ (peroxisome-proliferator-activated receptor δ). VPA has been shown to decrease folate levels, which can compromise DNA synthesis and result in hyperhomocysteinaemia and thus teratogenicity, although this is controversial [75] . VPA and its teratogenic analogues also activate PPARδ, a nuclear receptor regulating gene expression and thought to be involved in regulating cell growth. Non-teratogenic analogues do not lead to PPARδ activation, suggesting that the receptor acts as a sensor for teratogenicity. However, concentrations required to activate PPARδ in vitro are in the super-physiological range, suggesting VPA is not a direct ligand of the receptor [76] .
Other medical effects
The molecular mechanisms of VPA in migraine and potential AD treatment are poorly understood, and have limited published data on congener specificity. Similarities in neuronal excitability between seizures and migraine may suggest a common function of VPA on these disorders, in ion channel inhibition or to correct an imbalance in GABA levels [3] or through attenuation of overactive PLA 2 signalling, as discussed above. In AD treatment, VPA has been shown to decrease Aβ (amyloid β-peptide) production in vitro and in AD mice models by potentially inhibiting GSK3-mediated γ -secretase cleavage of APP (amyloid precursor protein), as well as reducing neuritic plaque formation and improving memory [77] . One of the side effects of VPA, hepatotoxicity, has been linked to the formation of toxic metabolites through mitochondrial β-oxidation, and analogue studies have shown that a terminal double bond is required for this effect [78] , with cyclic amide [78] and α-fluorinated analogues [28] providing non-hepatotoxic compounds with good therapeutic potential.
Summary
VPA has a range of current therapeutic roles that may broaden quickly in the near future, with a highly complex range of cellular targets and effects. To better understand these therapeutic effects, some studies have used a range of VPAlike chemicals to show structural specificity for each target or effect. Although comparative studies between effects are few, VPA has clearly separate effects on teratogenicity and inositol depletion/seizures, suggesting at least two discrete cellular targets. Furthermore, few compounds show increased potency with both seizure control and inositol depletion in mammalian neurons, suggesting that these effects also occur through different mechanisms. The continued analysis of novel compounds related to VPA may also identify new and improved treatments in its many therapeutic roles.
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